Insmed, Inc. (INSM) Receives Consensus Recommendation of “Hold” from Brokerages
Insmed, Inc. (NASDAQ:INSM) has earned an average rating of “Hold” from the ten research firms that are presently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $36.71.
INSM has been the subject of several analyst reports. BidaskClub downgraded shares of Insmed from a “sell” rating to a “strong sell” rating in a research note on Monday, August 14th. Evercore ISI began coverage on shares of Insmed in a research note on Wednesday, August 16th. They set an “outperform” rating and a $28.00 price objective for the company. Leerink Swann upped their price objective on shares of Insmed from $27.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, September 5th. ValuEngine raised shares of Insmed from a “sell” rating to a “hold” rating in a research note on Wednesday, September 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Insmed in a research note on Wednesday, September 6th.
Insmed (INSM) opened at $30.98 on Monday. Insmed has a one year low of $11.49 and a one year high of $32.94. The company has a debt-to-equity ratio of 0.13, a current ratio of 15.21 and a quick ratio of 15.21.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. GSA Capital Partners LLP acquired a new stake in Insmed during the 3rd quarter worth approximately $524,000. Iguana Healthcare Management LLC acquired a new stake in Insmed during the 3rd quarter worth approximately $1,561,000. Point72 Asset Management L.P. acquired a new stake in Insmed during the 3rd quarter worth approximately $3,446,000. Crestline Management LP acquired a new stake in Insmed during the 3rd quarter worth approximately $2,042,000. Finally, Janus Henderson Group PLC increased its position in Insmed by 140.2% during the 3rd quarter. Janus Henderson Group PLC now owns 3,960,748 shares of the biopharmaceutical company’s stock worth $123,615,000 after purchasing an additional 2,312,045 shares in the last quarter. 95.27% of the stock is owned by hedge funds and other institutional investors.
Insmed Company Profile
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC).
Receive News & Ratings for Insmed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed Inc. and related companies with MarketBeat.com's FREE daily email newsletter.